Tree peony bark extract and application thereof to preparation of medicines for treating pulmonary fibrosis

Abstract

The invention discloses a tree peony bark extract and application thereof to preparation of medicines for treating pulmonary fibrosis. At first, tree peony bark is extracted, and after that, pH value adjustment and heating for enzymolysis are carried out; after enzymolysis, the distillate is collected by the steam distillation method, left to stand and filtered to obtain crystal paeonol; the residual extracting solution and the leaves are filtered, and the herb residues are left for later use; the filtrate is subjected to concentration under reduced pressure and deproteinization, then ethanol is added, the mixture is left to stand, the ethanol solution is separated and collected for later use, and the sediment is washed to obtain cortex moutan polysaccharide; the stand-by ethanol solution is added into the stand-by herb residues for soaking and filtering, and the filtrate is subjected to concentration under reduced pressure and purification to obtain total glucosides of cortex moutan; the paeonol, the polysaccharide and the total glucosides are mixed to obtain the tree peony bark extract. Experimental results show that the tree peony bark extract can effectively inhibit epithelial-mesenchymal transition and lung fibroblast activation of alveolar epithelial cells so as to prevent pulmonary fibrosis from formation and development, and can be applied to preparation of medicines for treating pulmonary fibrosis.

Description

1. Technical field: [0001] The invention relates to the technical field of medicine, in particular to an extract of Cortex Moutan and its use in preparing medicines for preventing and treating pulmonary fibrosis. 2. Background technology: [0002] Pulmonary fibrosis is a malignant disease that seriously threatens human health and life. The average survival time of pulmonary fibrosis is 3 years after diagnosis, or 5 years after the onset of clinical symptoms. In the terminal stage of pulmonary fibrosis, lung transplantation is the only effective treatment. However, the lack of donors and high medical expenses limit the application of lung transplantation. Improving the efficacy of drugs has always been the goal pursued by medical workers. With the deepening of research on the pathogenesis of pulmonary fibrosis, it has been confirmed that the excessive accumulation of collagen, elastic fibers and protein sugars in the extracellular matrix (ECM) is its characteristic histopath...

AI Technical Summary

Problems solved by technology

However, up to now, there is no relevant research report on the prevention and treatment of pulmonary fibrosis by Moutan cortex extract, effective parts and active ingredients.

Images